Company intelligence / Profile preview
Neutrolis, Inc.
Cambridge, Massachusetts, United Statesneutrolis.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Neutrolis has developed a proprietary enzyme-based approach to dismantle NETs—web-like structures released by overactive neutrophils that drive tissue damage and chronic inflammation in autoimmune and inflammatory disorders. Their lead product NTR‑441, an engineered DNASE1L3 analog, has shown promise as a first-in-class therapy for multiple NET-driven conditions. The company’s pipeline includes programs for lupus, dry eye disease, COVID‑19/ARDS, and other chronic autoimmune conditions. Recent press releases indicate active advancement into the clinic with growing leadership and partnerships[3][4][5].
- Therapeutic areas
- ImmunologyInfectious Diseases
- Modalities
- Engineered enzymes (e.g., DNASE1L3 analogs)Protein therapeutics
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
LabCentral Golden Ticket awards from Pfizer and Bristol Myers Squibblicense agreement with University of Illinois Chicago for dry eye therapy patent[3][5].
Beyond the preview
Go deeper on Neutrolis, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neutrolis, Inc..